Impact Biomedical Inc. (IBO): Cash & Equivalents
$3.0K
As of 2025-12-31
+14.5%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.0K | -99.8% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $2.00M | n/m | 2026-03-11, Balance as of period end |
| 2023-12-31 | $1.0K | -50.0% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $2.0K | n/a | 2024-02-20, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $3.0K | -99.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $5.89M | -33.5% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $43.76M | +18.5% |
| Lunai Bioworks Inc. (LNAI) | 2026-06-30 | $1.71M | n/m |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $1.95M | -58.2% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $215.2K | -17.8% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $15.86M | -88.2% |
Compare IBO, LYEL, TLPH, NTHI side by side · Screen every company in Pharmaceutical Preparations ↗